2Q Revenues: $110.3 million (+34%)
2Q Earnings: $5.0 million (+51%)
YTD Revenues: $164.2 million (+31%)
YTD Loss: $15.2 million (earnings were $2.4 million YTD13)
Comments: This was the first full quarter of combined operations with Cangene.Product sales were $78.3 million, up 19%. Revenue from BioThrax was $67.5 million in the quarter, up 3%. Contract manufacturing revenue was $9.2 million in the quarter. R&D expenses were $37.4 million, up 23% primarily due to higher contract service costs, and includes increased technology and development expenses in both the Biodefense and Biosciences divisions.